Valentina Di Leo1, Paolo Biban2, Federico Mercolini1, Francesco Martinolli1, Andrea Pettenazzo1, G Perilongo3, Angela Amigoni4. 1. Pediatric Intensive Care Unit, Woman's and Child's Health Department, University Hospital, Via Giustiniani 3, 35128, Padua, Italy. 2. Neonatal and Pediatric Intensive Care Unit, Department of Pediatric, University Hospital, Verona, Italy. 3. Woman's and Child's Department, University Hospital, Padua, Italy. 4. Pediatric Intensive Care Unit, Woman's and Child's Health Department, University Hospital, Via Giustiniani 3, 35128, Padua, Italy. angela.amigoni@aopd.veneto.it.
Abstract
OBJECTIVE: To evaluate the health-related quality of life on a very long-term follow-up in patients treated with extracorporeal membrane oxygenation (ECMO) during neonatal and pediatric age. DESIGN: Prospective follow-up study. SETTING: Pediatric Intensive Care Unit of a tertiary-care University-Hospital. PATIENTS: Out of 20 neonates and 21 children treated with ECMO in our center, 24 patients underwent short-term neurological follow-up. Twenty of them underwent long-term neurological follow-up. INTERVENTION: Short-term follow-up was performed at 18 months and consisted in clinical evaluation, electroencephalography, and neuroimaging. Long-term follow-up was performed in 2017, at the mean period 19.72 years from ECMO (median 20.75, range 11.50-24.08) and consisted in a standardized questionnaires self-evaluation (PedsQL 4.0 Generic Core Scale) of health-related quality of life and an interviewed about the presence of organ morbidity, school level, or work position. MEASUREMENTS AND MAIN RESULTS: Sixty-one percent (25/41) of the patients survived within 30 days after ECMO treatment. Short-term follow-up was performed in 24 patients (1 patient but died before the evaluation): 21 patients (87%) showed a normal neurological status, and 3 developed severe disability. Long-term follow-up was performed in 20 long-term survivors (3 patients were not possible to be contacted and considered lost to follow-up): mean age of patients at long-term follow-up was 21.23 (median 20.96, range 13.33-35.58) years; 90% (18/20) of them have no disability with a complete normal quality of life and 95% have no cognitive impairment. CONCLUSIONS: ECMO represents a life-saving treatment for infants and children with respiratory and/or heart failure; survivors show a good quality of life comparable to healthy peers.
OBJECTIVE: To evaluate the health-related quality of life on a very long-term follow-up in patients treated with extracorporeal membrane oxygenation (ECMO) during neonatal and pediatric age. DESIGN: Prospective follow-up study. SETTING: Pediatric Intensive Care Unit of a tertiary-care University-Hospital. PATIENTS: Out of 20 neonates and 21 children treated with ECMO in our center, 24 patients underwent short-term neurological follow-up. Twenty of them underwent long-term neurological follow-up. INTERVENTION: Short-term follow-up was performed at 18 months and consisted in clinical evaluation, electroencephalography, and neuroimaging. Long-term follow-up was performed in 2017, at the mean period 19.72 years from ECMO (median 20.75, range 11.50-24.08) and consisted in a standardized questionnaires self-evaluation (PedsQL 4.0 Generic Core Scale) of health-related quality of life and an interviewed about the presence of organ morbidity, school level, or work position. MEASUREMENTS AND MAIN RESULTS: Sixty-one percent (25/41) of the patients survived within 30 days after ECMO treatment. Short-term follow-up was performed in 24 patients (1 patient but died before the evaluation): 21 patients (87%) showed a normal neurological status, and 3 developed severe disability. Long-term follow-up was performed in 20 long-term survivors (3 patients were not possible to be contacted and considered lost to follow-up): mean age of patients at long-term follow-up was 21.23 (median 20.96, range 13.33-35.58) years; 90% (18/20) of them have no disability with a complete normal quality of life and 95% have no cognitive impairment. CONCLUSIONS: ECMO represents a life-saving treatment for infants and children with respiratory and/or heart failure; survivors show a good quality of life comparable to healthy peers.
Entities:
Keywords:
Children; Extracorporeal membrane oxygenation; Morbidity; Mortality; Neurologic disorders; Quality of life
Authors: Gonzalo Garcia Guerra; Charlene M T Robertson; Gwen Y Alton; Ari R Joffe; Elham Khodayari Moez; Irina A Dinu; David B Ross; Ivan M Rebeyka; Laurance Lequier Journal: Pediatr Crit Care Med Date: 2014-10 Impact factor: 3.624
Authors: Laurance Lequier; Ari R Joffe; Charlene M T Robertson; Irina A Dinu; Yuttapong Wongswadiwat; Natalie R Anton; David B Ross; Ivan M Rebeyka Journal: J Thorac Cardiovasc Surg Date: 2008-06-02 Impact factor: 5.209
Authors: Marilyn C Morris; Richard F Ittenbach; Rodolfo I Godinez; Joel D Portnoy; Sarah Tabbutt; Brian D Hanna; Timothy M Hoffman; J William Gaynor; James T Connelly; Mark A Helfaer; Thomas L Spray; Gil Wernovsky Journal: Crit Care Med Date: 2004-04 Impact factor: 7.598
Authors: Cindy S Barrett; Susan L Bratton; Joshua W Salvin; Peter C Laussen; Peter T Rycus; Ravi R Thiagarajan Journal: Pediatr Crit Care Med Date: 2009-07 Impact factor: 3.624
Authors: José A Hordijk; Sascha C Verbruggen; Corinne M Buysse; Elisabeth M Utens; Koen F Joosten; Karolijn Dulfer Journal: Qual Life Res Date: 2022-03-31 Impact factor: 3.440